Relationship between vaginal group B streptococcus colonization in the early stage of pregnancy and preterm birth: a retrospective cohort study

Sho Tano 1,2*, Takuji Ueno 1, Michinori Mayama 1, Takuma Yamada 1, Takehiko Takeda 1, Kaname Uno 1, Masato Yoshihara 2, Mayu Ukai 1, Tepppei Suzuki 1, Yasuyuki Kishigami 1 and Hidenori Oguchi 1

Abstract

Background: Although infection and inflammation within the genital tract during pregnancy is considered a major risk factor for spontaneous preterm birth (PTB), there are few studies on association between vaginal microorganisms in the early stage of pregnancy and PTB. The aim of this study was to investigate relationship between vaginal Group B streptococcus (GBS) colonization, a leading cause of infection during pregnancy, in the early stage of pregnancy and PTB.

Methods: This single-center, retrospective cohort study utilized data from 2009 to 2017 obtained at TOYOTA Memorial Hospital. Women with singleton pregnancies who underwent vaginal culture around 14 weeks of gestation during their routine prenatal check-up were included. Vaginal sampling for Gram staining and culture was performed regardless of symptoms. GBS colonization was defined as positive for GBS latex agglutination assay. Statistical analysis was performed to determine the factors associated with PTB.

Results: Overall 1079 singleton pregnancies were included. GBS (5.7%) and Candida albicans (5.5%) were the most frequently observed microorganisms. The incidence of PTB (before 34 and before 37 weeks of gestation) were significantly higher in the GBS-positive group than in the GBS-negative group (6.6% vs 0.5%, \( p = 0.001 \) and 9.8% vs 4.3%, \( p = 0.047 \)). Our multivariable logistic regression analysis revealed that GBS colonization was a factor associated with PTB before 34 and before 37 weeks of gestation (Odds ratio [OR] 15.17; 95% confidence interval [CI] 3.73–61.74, and OR 2.42; 95%CI 1.01–5.91, respectively).

Conclusions: The present study found that vaginal GBS colonization in the early stage of pregnancy was associated with PTB. Our study indicates that patients at a high risk for PTB can be extracted by a simple method using conventional culture method.

Keywords: Preterm birth, Group B Streptococcus, Vaginal flora
Background
The presence of infection and inflammation within the genital tract during pregnancy has been considered a major risk factor for spontaneous preterm birth (PTB) [1]. The primary colonizing bacteria in healthy pregnant women are Lactobacillus, which produce protection against pathogenic species [2]. Bacterial vaginosis (BV) diagnosed based on Nugent scoring system (Table S1) is an independent risk factor for PTB. The risk for PTB is reported to be higher if BV occurs in the early stage of pregnancy [3]. The Nugent scoring method quantifies the presence of Lactobacillus morphotypes compared to Gram negative organisms and Gram variable Actinobacteria [4].

Regarding vaginal microorganisms, Group B streptococcus (GBS) is a leading cause of infection during pregnancy, and vaginal GBS colonization is a risk factor for developing neonatal GBS disease [5]. Detecting GBS during the last 5 weeks before delivery is believed to be accurate in predicting the presence of GBS in the mother during childbirth [6]. It is well known that vertical transmission of this organism in babies can be prevented by administration of prophylactic antibiotics to mothers during labor, so GBS screening is usually carried out at 35–37 weeks of gestation [7]. Also, there is a higher possibility of developing maternal GBS related diseases such as urinary tract infection or bacteremia [8, 9], which is worth noting that maternal infection can lead to PTB. Despite the practical importance of vaginal GBS colonization, limited studies have discussed the association between PTB and vaginal GBS colonization in the early stage of pregnancy. Although vaginal GBS colonization happens transiently, intermittently, or chronically in pregnant women [10], pregnant women who have vaginal GBS colonization in the early stage of pregnancy can be more affected by GBS.

The present study aims to investigate the prevalence of abnormal vaginal microorganisms during pregnancy and the relationship between GBS colonization in the early stage of pregnancy and PTB.

Methods
Study population
A single-center, retrospective cohort study was conducted using electronic health records from 2009 to 2017 obtained from TOYOTA Memorial Hospital, a perinatal center in Toyota city, Aichi, Japan. Women with pregnancies who underwent vaginal culture in the early stage of pregnancy (around 14 weeks of gestation) during their routine prenatal check-up at our hospital were included, whereas those who had known risks for spontaneous PTB (previous PTB, uterine malformation, myoma uteri or multiple pregnancies) or could require PTB due to medical indication (preeclampsia, fetal growth restriction, fetal malformation or intra-uterine fetal demise) were excluded at analysis. The requirement for informed consent was waived by the ethics committee due to the retrospective nature of the study. The ethics committee of TOYOTA Memorial Hospital approved this study.

Sample collection
Vaginal sampling for Gram staining and culture were performed in the early stage of pregnancy for all pregnant women, regardless of the symptoms. After the insertion of sterile speculum using water-based lubrication, a smear was taken from the vagina using a sterile cotton swab. The Gram stain-based Nugent score was calculated, and the entire specimen was incubated on Nissui Separated Sheep Blood Agar/Chocolate Agar EX II® (Nissui Pharmaceutical Co., Ltd., Japan) for 24 h at 35°C in 5% CO₂, according to the manufacturer’s instruction. Negative plates were re-incubated for an additional 24 h and then reexamined. Positive plates were tested using GBS latex agglutination assay, Strept LA® (Denka Seiken Co., Ltd., Japan). It was selected based on cost, availability, and ease of use. GBS colonization was defined as positive for Strept LA®, and the detection of GBS during pregnancy prompted the administration of ampicillin during labor.

Factors assessed
In order to investigate the relationship between vaginal GBS detection in the early stage of pregnancy and PTB, patients were divided into the GBS-positive group and the GBS-negative group according to the result of vaginal culture in the early stage of pregnancy. Baseline maternal characteristics including maternal age and complications such as chronic hypertension, diabetes mellitus and thyroid diseases were collected, whereas the incidence of BV (Nugent score of ≥7 points) and the results of vaginal culture were examined. Nullipara was defined as having no previous history of a delivery after 20 weeks of gestation. Overweight is defined as a prepregnant body mass index (BMI) of 25 or more, and thyroid disease includes hyperthyroidism and hypothyroidism. Gestational diabetes mellitus (GDM) is diagnosed according to the oral glucose tolerance test (OGTT) international consensus criteria; the fasting plasma glucose level exceeds 92 mg/dL, the 1 h level exceeds 180 mg/dL or the 2 h level exceeds 153 mg/dL after 75 g glucose loading. Gestational age at delivery, birth weight, premature rupture of membranes (PROM) were defined as delivery outcomes. The preterm PROM (pPROM) is defined as the onset of amniotic fluid leakage from the vagina before the onset of uterine contractions at < 37 weeks of gestation [11], and the diagnosis of pPROM is based on both history and physical
examination: visualization of pooling of amniotic fluid in the vaginal fornix or detecting insulin growth factor binding protein-1 (IGFBP-1) using check PROM® (Alfresa Pharma Co., Ltd., Japan). Statistical analysis was performed to determine the risk for PTB (earlier than 34 weeks and earlier than 37 weeks).

**Statistical analysis**

Data are presented as means ± standard deviation or median [range] for continuous variables and n (%) for categorical variables. Baseline characteristics between GBS group and control group were compared using \( \chi^2 \) test, Student’s t-test or Mann–Whitney’s U test, as appropriate. Associations of individual parameters and PTB < 37 weeks of gestation or PTB < 34 weeks of gestation were calculated using univariable and multivariable regression analyses. Variables with \( p \)-values of less than 0.25 in the univariable regression analysis were entered to multivariable logistic regression analysis using backward elimination method. A \( p \)-value of < 0.05 was considered statistically significant. Statistical analyses were conducted using SPSS version 26.0 for Windows software (SPSS, Inc., Chicago, IL, USA).

**Results**

**Participants**

A total of 1390 pregnancies underwent vaginal culture examination in the early stage of pregnancy (around 14 weeks of gestation) at our institution during the study period. We excluded 311 patients because of known risks for spontaneous PTB (multiple pregnancy, previous PTB, uterine malformation or myoma uteri) or need for PTB due to medical indication (fetal growth restriction, preeclampsia or intra-uterine fetal demise; Fig. 1). The remaining 1079 patients were finally included.

**Vaginal flora**

The prevalence of BV in the early stage of pregnancy was 6.9% (Table 1), with the most frequently observed microorganisms being GBS (5.7%) and *Candida albicans* (5.5%). The frequency of detecting GBS and *Candida albicans* from vaginal and rectal culture during the 3rd trimester as routine check-up was 9.5 and 7.2%, respectively (Table 1). The prevalence of BV in the early stage of pregnancy was lower in the GBS-positive group but there was no significant difference (3.3% vs 7.1%, \( p = 0.429 \); Table S2). Among 61 pregnant women who detected GBS in the early stage of pregnancy, 31 (50.1%) were also detected with GBS during the 3rd trimester. Of the remaining 30 patients, 26 were GBS-negative during the 3rd trimester, and 4 did not undergo vaginal and rectal cultures during the 3rd trimester. Of the 26 patients with GBS-negative during the 3rd trimester, 1 was complicated with GBS and symptomatic BV in the early stage of pregnancy, and was treated with metronidazole before the 3rd trimester.

**Association between GBS colonization and pPROM**

As shown in Table 2, there were no significant differences in the baseline data including gestational age at vaginal culture, maternal age, and the incidence of diabetes mellitus and thyroid disease between GBS-positive

---

**Fig. 1** Flow chart describing subjects in this study. *Of the 19 patients, 3 were GBS-positive in early stage of pregnancy. **Of the 27 patients, I was GBS-positive in early stage of pregnancy.
and GBS-negative groups. The rate of nulliparity was significantly higher in the GBS-positive group (70.8% vs. 58.0%, *p* = 0.042), but there were no patients having episodes of cervical insufficiency among GBS-positive patients included. The incidence of pPROM and term PROM were higher in the GBS-positive group, but there were no significant differences (3.3% vs. 1.9%, *p* = 0.335 and 23.0% vs. 14.2%, *p* = 0.062, respectively). As shown in Fig. 2, all 21 pPROM patients delivered at < 37 weeks of gestation, and 3 of 4 patients with pPROM at < 34

| GA at examination, wk [range] | Early stage of pregnancy | 3rd trimester |
|-----------------------------|--------------------------|-------------|
| Vagina n = 1079             |                          |             |
| Nugent score                | 14.4 [11.3–17.7]         | 34.6 [33.1–36.9] |
| 0–3                         | 888 (82.3)               | 903 (87.4)  |
| 4–6                         | 117 (10.8)               | 75 (7.3)    |
| 7–10 (Bacterial vaginosis)  | 74 (6.9)                 | 55 (5.3)    |

**Abnormal bacterial colonization**

**GBS**
- Positive: 61 (5.7)
- Negative: 1018 (94.3)

**Candida albicans**
- Positive: 59 (5.5)
- Negative: 1020 (94.5)

**Candida glabrata**
- Positive: 25 (2.3)
- Negative: 1054 (97.7)

**Candida krusei**
- Positive: 2 (0.2)
- Negative: 1077 (99.8)

**CNS**
- Positive: 18 (1.7)
- Negative: 1061 (98.3)

**Staphylococcus aureus**
- Positive: 10 (0.9)
- Negative: 1069 (99.1)

**Enterococcus species**
- Positive: 7 (0.6)
- Negative: 1072 (99.4)

**Escherichia coli**
- Positive: 2 (0.2)
- Negative: 1077 (99.8)

**MRSA**
- Positive: 0 (0.0)
- Negative: 1079 (100)

**Others**
- Positive: 11 (1.0)
- Negative: 1068 (99.0)

| GA at examination, wk [range] | Early stage of pregnancy | 3rd trimester |
|-----------------------------|--------------------------|-------------|
| Vagina n = 1033             |                          |             |

**Table 1** Prevalence of vaginal microorganisms in the early stage of pregnancy and during the 3rd trimester

| GA at examination, wk [range] | Early stage of pregnancy | 3rd trimester |
|-----------------------------|--------------------------|-------------|
| Vagina n = 1079             |                          |             |
| Nugent score                | 14.4 [11.3–17.7]         | 34.6 [33.1–36.9] |
| 0–3                         | 888 (82.3)               | 903 (87.4)  |
| 4–6                         | 117 (10.8)               | 75 (7.3)    |
| 7–10 (Bacterial vaginosis)  | 74 (6.9)                 | 55 (5.3)    |

**Abnormal bacterial colonization**

**GBS**
- Positive: 61 (5.7)
- Negative: 1018 (94.3)

**Candida albicans**
- Positive: 59 (5.5)
- Negative: 1020 (94.5)

**Candida glabrata**
- Positive: 25 (2.3)
- Negative: 1054 (97.7)

**Candida krusei**
- Positive: 2 (0.2)
- Negative: 1077 (99.8)

**CNS**
- Positive: 18 (1.7)
- Negative: 1061 (98.3)

**Staphylococcus aureus**
- Positive: 10 (0.9)
- Negative: 1069 (99.1)

**Enterococcus species**
- Positive: 7 (0.6)
- Negative: 1072 (99.4)

**Escherichia coli**
- Positive: 2 (0.2)
- Negative: 1077 (99.8)

**MRSA**
- Positive: 0 (0.0)
- Negative: 1079 (100)

**Others**
- Positive: 11 (1.0)
- Negative: 1068 (99.0)

Data are presented as median [range] for continuous variables and n (%) for categorical variables.

GA Gestational age, GBS Group B Streptococcus, CNS Coagulase-negative staphylococci, MRSA Methicillin-resistant Staphylococcus aureus.
| Table 2 | Comparison of baseline characteristics among women divided according to vaginal flora in early stage of pregnancy |
|---------|----------------------------------------------------------------------------------------------------------|
|         | GBS in early stage of pregnancy                                                                                     |
|         | Positive | Negative | p-value |
| GA at examination, weeks, median [range] | 14.3 [13.6–16.3] | 14.4 [11.3–17.7] | 0.863 |
| Maternal age, years old | 34.8 ± 4.6 | 34.2 ± 4.9 | 0.277 |
| Nullipara | | | |
| Yes | 43 (70.5) | 594 (58.3) | 0.042* |
| No | 18 (29.5) | 424 (41.7) | |
| Overweight (BMI ≥ 25) | | | |
| Yes | 6 (9.8) | 99 (9.7) | 0.977 |
| No | 55 (90.2) | 919 (90.3) | |
| Diabetes mellitus | | | |
| Yes | 3 (4.9) | 27 (2.7) | 0.417 |
| No | 58 (95.1) | 991 (97.3) | |
| Thyroid disease | | | |
| Yes | 2 (3.3) | 71 (7.0) | 0.427 |
| No | 59 (96.7) | 947 (93.0) | |
| GDM | | | |
| Yes | 5 (8.2) | 123 (12.1) | 0.373 |
| No | 56 (91.8) | 895 (87.9) | |
| Preterm PROM | | | |
| Yes | 2 (3.3) | 19 (1.9) | 0.335 |
| No | 59 (96.7) | 999 (98.1) | |
| Term PROM | | | |
| Yes | 14 (23.0) | 146 (14.3) | 0.062 |
| No | 47 (77.0) | 872 (85.7) | |
| GA at delivery, weeks, median [range] | 39.4 [29.9–42.0] | 39.4 [32.3–42.7] | 0.938 |
| Preterm birth < 34 weeks | | | |
| Yes | 4 (6.6) | 5 (0.5) | 0.001* |
| No | 57 (93.4) | 1013 (99.5) | |
| Preterm birth < 37 weeks | | | |
| Yes | 6 (9.8) | 44 (4.3) | 0.047* |
| No | 55 (90.2) | 974 (95.7) | |
| Sex | | | |
| Male | 32 (52.5) | 533 (52.4) | 0.988 |
| Female | 29 (47.5) | 485 (47.6) | |
| Birth weight, kg, median [range] | 3.0 [1.4–4.4] | 3.1 [1.5–4.3] | 0.433 |
| Apgar score at 1 min | | | |
| Low Apgar score (< 7 points) | 6 (9.8) | 53 (5.2) | 0.122 |
| ≥ 7 points | 55 (90.2) | 965 (94.8) | |
| Apgar score at 5 min | | | |
| Low Apgar score (< 7 points) | 3 (4.9) | 13 (1.3) | 0.057 |
| ≥ 7 points | 58 (95.1) | 1005 (98.7) | |
| NICU admission | | | |
| Yes | 10 (16.4) | 109 (10.7) | 0.168 |
weeks of gestation delivered at < 34 weeks of gestation. The time to delivery of the 4 patients with pPROM at < 34 weeks of gestation was 0, 2, 7, and 28 days, respectively, and the shortest one was GBS-positive in the early stage of pregnancy.

**Association between GBS colonization and PTB**

Table 3 revealed GBS colonization in the early stage of pregnancy was associated with increased risk for PTB at < 37 weeks (9.8% vs. 4.3%, Odds Ratio [OR] 2.42; 95% confidence interval [CI] 1.01–5.91) and at < 34 weeks (6.6% vs. 0.5%, OR 14.22; 95% CI 3.72–54.38). Multivariable logistic regression analyses to identify factors associated with PTB < 37 weeks of gestation and one of PTB < 34 weeks of gestation are shown in Table 4. Variables with p-values of less than 0.25 in the bivariable regression analysis were entered to multivariable logistic regression analysis using backward elimination method, and the final set for identifying the risks of PTB < 37 weeks of gestation was only “GBS-positive in the early stage of pregnancy” (OR 2.42; 95%CI 1.01–5.91). In addition to GBS-positive in the early stage of pregnancy, diabetes mellitus was associated with increased odds of PTB < 34 weeks of gestation in the multivariable regression analysis (OR 15.17; 95% CI 3.73–61.74, and OR 8.06; 95%CI 1.36–47.78, respectively).

**Discussion**

A previous retrospective cohort study reported that GBS detection from 26 to 28 weeks of gestation was a risk factor for PTB before 37 weeks of gestation (OR: 2.24) [12]. Furthermore, our findings suggested that GBS

---

**Table 2** Comparison of baseline characteristics among women divided according to vaginal flora in early stage of pregnancy (Continued)

| GBS in early stage of pregnancy | Positive n = 61 | Negative n = 1018 | p-value |
|-------------------------------|----------------|-------------------|---------|
| No                            | 51 (83.6)      | 909 (89.3)        |         |
| Neonatal GBS disease          |                |                   |         |
| Yes                           | 0 (0.0)        | 0 (0.0)           |         |
| No                            | 61 (100)       | 1018 (100)        |         |

Data are presented as means ± standard deviation or median [range] for continuous variables and n (%) for categorical variables.

GBS: Group B Streptococcus, GA: Gestational age, BMI: Body mass index, GDM: Gestational diabetes mellitus, PROM: Premature rupture of membranes, NICU: Neonatal Intensive Care Unit.

*Statistically significant
Table 3 Comparison of characteristics of patients divided according to preterm birth

| Variable                        | Preterm birth < 34 weeks of gestation | Preterm birth < 37 weeks of gestation |
|---------------------------------|---------------------------------------|---------------------------------------|
|                                 | Yes n (%) | No n (%) | OR 95%CI | p-value | Yes n (%) | No n (%) | OR 95%CI | p-value |
| Maternal age, years old         |           |          |          |         |           |          |          |         |
|                                 | 0.98      | (0.86–1.12) | 0.748    |         | 0.97      | (0.91–1.02) | 0.210    |
| Nullipara                       |           |          |          |         |           |          |          |         |
| Yes                             | 3 (0.5)   | 634 (99.5) | 0.34     | (0.09–1.38) | 0.133    | 25 (3.9) | 612 (96.1) | 0.68     | (0.39–1.20) | 0.186    |
| No                              | 6 (1.4)   | 336 (98.6) | Ref      | Ref      | 25 (5.7) | 417 (94.3) | Ref      | Ref      |
| Overweight (BMI ≥ 25)           |           |          |          |         |           |          |          |         |
| Yes                             | 0 (0.0)   | 105 (100) | –        | –        | –        | 2 (1.9)  | 103 (98.1) | 0.375    | (0.09–1.56) | 0.178    |
| No                              | 9 (0.9)   | 965 (90.1) |           |          | 48 (4.9) | 926 (95.1) | Ref      | Ref      |
| Diabetes mellitus               |           |          |          |         |           |          |          |         |
| Yes                             | 2 (6.7)   | 28 (93.3) | 10.63    | (2.11–53.50) | 0.004*  | 3 (10.0) | 27 (90.0) | 2.37     | (0.69–8.09) | 0.169    |
| No                              | 7 (0.7)   | 1042 (99.3) | Ref      | Ref      | 47 (4.5) | 1002 (95.5) | Ref      | Ref      |
| Thyroid disease                 |           |          |          |         |           |          |          |         |
| Yes                             | 0 (0.0)   | 73 (100)  | –        | –        | –        | 3 (4.1)  | 70 (95.9) | 0.87     | (0.27–2.88) | 0.825    |
| No                              | 9 (0.9)   | 997 (90.1) |           |          | 47 (4.7) | 959 (95.3) | Ref      | Ref      |
| GDM                             |           |          |          |         |           |          |          |         |
| Yes                             | 0 (0.0)   | 128 (100) | –        | –        | –        | 2 (1.6)  | 126 (98.4) | 0.30     | (0.07–1.26) | 0.099    |
| No                              | 9 (0.9)   | 942 (90.1) |           |          | 48 (5.0) | 903 (95.0) | Ref      | Ref      |
| BV in the early stage of pregnancy |         |          |          |         |           |          |          |         |
| Yes                             | 0 (0.0)   | 74 (100)  | –        | –        | –        | 3 (4.1)  | 71 (95.9) | 0.86     | (0.26–2.84) | 0.806    |
| No                              | 9 (0.9)   | 996 (90.1) |           |          | 47 (4.7) | 958 (95.3) | Ref      | Ref      |
| GBS-positive in the early stage of pregnancy |         |          |          |         |           |          |          |         |
| Yes                             | 4 (6.6)   | 57 (93.4) | 14.22    | (3.72–54.38) | < 0.001* | 6 (9.8)  | 55 (90.2) | 2.42     | (1.01–5.91) | 0.045*    |
| No                              | 5 (0.5)   | 1013 (99.5) | Ref      | Ref      | 44 (4.3) | 974 (95.7) | Ref      | Ref      |
| BV during the 3rd trimester     |           |          |          |         |           |          |          |         |
| Yes                             | –        | –        | –        | –        | 2 (3.6)  | 53 (96.4) | 1.24     | (0.29–5.31) | 0.777    |
| No                              | –        | –        | –        | –        | 29 (3.0) | 949 (97.0) | Ref      | Ref      |
| GBS-positive during the 3rd trimester |         |          |          |         |           |          |          |         |
| Yes                             | –        | –        | –        | –        | 5 (5.1)  | 93 (94.9) | 1.88     | (0.71–5.01) | 0.207    |
| No                              | 26 (2.8) | 909 (97.2) |           |          | 295 (4.0) | 6896 (96.0) | Ref      | Ref      |

*p-value for bivariable regression analysis

| Variable                        | Preterm birth < 34 weeks of gestation | Preterm birth < 37 weeks of gestation |
|---------------------------------|---------------------------------------|---------------------------------------|
|                                 | Yes n (%) | No n (%) | OR 95%CI | p-value | Yes n (%) | No n (%) | OR 95%CI | p-value |
| Nullipara                       | 0.30      | (0.07–1.26) | 0.298    |         | –        | –        | –        |         |
| Diabetes mellitus               | 8.06      | (1.36–47.78) | 0.022*  |         | –        | –        | –        |         |
| GBS-positive in the early stage of pregnancy | 15.17 (3.73–61.74) | < 0.001* | 2.42 (1.01–5.91) | 0.045* |
colonization around 14 weeks of gestation was associated with PTB before 37 weeks of gestation (OR: 2.42, \( p = 0.045 \)) as well as for PTB before 34 weeks of gestation (OR: 15.17, \( p < 0.001 \)). To the best of our knowledge, only one report has discussed the relationship between vaginal culture during the 1st trimester and PTB [13]. Although the report showed no significant difference in the prevalence of PTB between the GBS-positive (\( n = 10 \)) and GBS-negative (\( n = 211 \)) groups, the number of cases analyzed was relatively less. In addition to PTB, the incidence of PROM was also relatively high in the GBS-positive group, although there was no significant difference. Our study revealed that diabetes is also one of the factors associated with PTB, as reported in previous reports [1]. One case-control study concluded that vaginal GBS colonization at 28–36 weeks of gestation was discriminant factors for pPROM according to stepwise discriminant analysis [14]. Our study yielded results consistent with this report, but a larger sample would be needed to demonstrate this association. Similarly, multiparity is reported as a risk of PTB [15], and our multivariable logistic regression analysis suggests that nulliparity was associated with decreased odds of PTB < 34 weeks of gestation, although there is no significant difference.

In the present study, we observed a relatively low rate of GBS detection (5.7%) in the early stage of pregnancy, whereas a previous study reported varying colonization rates from 5 to 49% [12]. One possible reason for the low detection rate in our study can be that the diagnosis of GBS is based on a rapid test. Assuming that our data revealed high colonization, such a result would support an association between high vaginal colonization in the early stage of pregnancy and PTB. Some researchers recommend performing the polymerase chain reaction (PCR) assay in addition to conventional culture method to prevent false negative and for the use of appropriate prophylactic antibiotics [16, 17], but conventional culture method rather than PCR is reported to be related with neonatal GBS infection itself [18]. No PCR was performed at our hospital, but none of the patients included in this study developed neonatal GBS disease. Early-onset GBS disease has become relatively uncommon in recent years due to many guidelines recommending continued efforts for preventing neonatal GBS disease [19]. Although the prevention of neonatal GBS infection is important, the higher prevalence of PTB suggests the need to focus on PTB during maternal GBS infection.

Our study has several strengths. First, our study indicates that patients at high risk for PTB can be extracted by a simple method using conventional culture method rather than PCR. It allows any facilities including local primary facilities to easily recognize high risk pregnant women. BV is also a known risk factor for PTB, but Nugent score, a diagnostic criteria, has the disadvantage of being laborious and difficult to reproduce [20], which hampers universal use. Second, this study has an important major, benefit of a large sample size. Many studies aimed at determining factors associated with PTB are limited by sample size, and this study addresses that. But our study has several limitations. First, the lack of data about sexually transmitted infections (STIs), which is reported to be a risk factor for PTB in the context of vaginal microbiota [21]. Second, the lack of performing GBS serotyping. Some studies emphasize the importance of serotyping of GBS because it is suggested that GBS has different clinical features depending on its serotype [22, 23]. Third is the lack of placental pathology that could have provided evidence to support the relationship between GBS infection and chorioamnionitis and placental membrane inflammation. Fourth, identifying the risk of PTB before 34 weeks of gestation is clinically valuable, but the number of cases is not large enough to obtain highly confident results about it. The multivariable regression analyses of identifying the risks of PTB < 34 weeks of gestation showed large 95% confident intervals, which are due to a small number of patients with PTB < 34 weeks of gestation. However, it is noteworthy that 4 of the 9 cases of PTB < 34 weeks of gestation were GBS positive in early stage of pregnancy.

Given that the present study examined the relationship between GBS detection in the early stage of pregnancy and delivery outcomes, the presence or absence of symptoms or treatment was not considered. Accordingly, to further investigate the association between GBS infection and PTB, additional research, including pathological evaluation or GBS serotyping or treatment effects, is imperative. Nevertheless, we believe that the present study could serve as the basis for further research.

Conclusion

The present study found that vaginal GBS colonization in the early stage of pregnancy was associated with PTB. Future studies that consider treatment effects are necessary to translate to the clinical setting. Nevertheless, our results suggest that early prenatal screening for vaginal GBS colonization can be advantageous, given that it could help identify pregnant women at risk for PTB.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12884-021-03624-9.

Additional file 1: Table S1. Nugent score. Table S2. Association between BV and GBS detection during the 3rd trimester.

Abbreviations

PTB: Preterm birth; BV: Bacterial vaginosis; GBS: Group B streptococcus; PROM: Premature rupture of membranes; OR: Odds ratio; 95%CI: 95%
References
1. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008. https://doi.org/10.1016/S0140-6736(08)60074-4.
2. Kindinger LM, et al. The interaction between vaginal microbiota, cervical length, and vaginal progesterone treatment for preterm birth risk. Microbiome. 2017;5:1–14.
3. Leitch H, et al. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol. 2003;189(1):139–47.
4. van den Munckhof EHA, et al. Comparison of Amsel criteria, Nugent score, culture and two CE-IVD marked quantitative real-time PCRs with microbiota analysis for the diagnosis of bacterial vaginosis. Eur J Clin Microbiol Infect Dis. 2019;55:65–66. https://doi.org/10.1007/s10096-019-03538-x.
5. Stoll BJ, et al. Early onset neonatal sepsis: the burden of group B streptococcal and E. coli disease continues. Pediatrics. 2019;143:1–8.
6. Tano et al. BMC Pregnancy and Childbirth (2021) 21:141
7. Son K-A, et al. Prevalence of vaginal microorganisms among pregnant women according to trimester and association with preterm birth. Obstet Gynecol Sci. 2018;61:38.
8. Zhang LX, et al. A bayesian stepwise discriminant model for predicting risk factors of preterm premature rupture of membranes: a case-control study. Chin Med J. 2017;130:2416–22.
9. Muniro Z, Tarimo CS, Mahande MJ, Maro E, Mchome B. Grand multiparity as a predictor of adverse pregnancy outcome among women who delivered at a tertiary hospital in Northern Tanzania. BMC Pregnancy Childbirth. 2019;19(1):122.
10. Moussavi SM, Hosseini SM, Mashouf RY, Arabestani MR. Identification of group B streptococci using 16S rRNA, dfr, sclpB, and atr genes in pregnant women by PCR. Acta Med Iran. 2016;54:765–70.
11. Fullston EF, Doyle MJ, Higgins MF, Knowles SJ. Clinical impact of rapid polymerase chain reaction (PCR) test for group B Streptococcus (GBS) in term women with ruptured membranes. Ir J Med Sci. 2019;188:1269–74.
12. Vieira LL, et al. Group B Streptococci detection in pregnant women: comparison of qPCR assay, culture, and the Xpert GBS rapid test, vol. 0. 2019; p. 1–8.
13. Verani JR, McGee L, Schrag SJ. Centre for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease, revised guidelines 2010. Mmwr. 2010;59:662–7.
14. Menard J, Fenollar F, Henry M, Bretelle F, Raoult D. Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial Vaginosis. Clin Infect Dis. 2008. https://doi.org/10.1086/588661.
15. Fuchs E, Dwiggin M, Lokken E, Unger JA, Eckert LO. Influence of sexually transmitted infections in pregnant adolescents on preterm birth and Chorioamnionitis. Infect Dis Obstet Gynecol. 2020;2020:1–10.
16. Zhu Y, et al. Etiological serotype and genotype distributions and clinical characteristics of group B streptococcus –inducing invasive disease among term women in South China; 2020. p. 1–8.
17. Mohamed AM, et al. Group B Streptococcus colonization, antibiotic susceptibility, and serotype distribution among Saudi pregnant women. Infect Chemother. 2020;52:70–81.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.